 Health Newstrack |
Bevacizumab Not Effective in Advanced Lung Cancer in the Elderly
Medscape April 17, 2012 — The addition of the targeted therapy bevacizumab (Avastin, Genentech) to standard chemotherapy for advanced nonsmall cell lung cancer (NSCLC) did not significantly increase survival rates for patients 65 years and older, according to … Avastin No Help in Advanced NSCLC Adding Drug to Standard Chemotherapy Provides No Survival Benefit for Older … Study examines drug regimen for the treatment of non-small cell lung cancer … |
View full post on lung cancer – Google News
